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Novel Diagnostic and Therapeutic 
Approach to Antibody-Mediated 
Rejections in Heart Transplantation
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Abstract
Despite the improvement of immunosuppressive therapy in heart transplanta-
tion (HTx), antibody-mediated rejection (AMR) is still a great obstacle to prolong 
cardiac graft survival. Anti-donor-specific antibodies (DSAs), especially anti-donor 
human leukocyte antigen (HLA) antibody, lead to heart graft failure resulting in 
hemodynamic consequence and often in the recipient death. To prevent hyperacute 
rejection, prospective complement-dependent cytotoxicity test has been performed 
in every cardiac donor in Japan. But in other solid organ transplantations, flow 
cytometry crossmatch has been recently recommended to crossmatch to select the 
recipient in Japan as well as the world. However, flow cytometry is too sensitive to 
select the recipient, because not all DSAs determined by flow cytometry are cyto-
toxic to the cardiac graft. On the first complement classical pathway, alloantibodies 
bind to HLA antigens on cells of the graft and then recruit C1q, which is essential 
to make membrane attack complex and kill the cell. We review a role of the novel 
monitoring method of complement pathway regarding C1q in occurrence of AMR 
and its diagnostic and therapeutic significance in managing AMR in HTx.
Keywords: heart transplantation, antibody-mediated rejection, sensitization, 
complement binding donor-specific antibodies, C1q assay
1. Introduction
Although immunosuppressive therapy in heart transplantation (HTx) has been 
remarkably improved, antibody-mediated rejection (AMR) is still a great obstacle 
to prolong cardiac graft survival [1, 2]. AMR may develop when recipient antibod-
ies against donor human leukocyte antigen (HLA) on the endothelial cells exist in 
the recipient serum [3]. The presence of circulating anti-donor-specific antibodies 
(DSAs) has several impacts on clinical outcomes both before and after HTx. The 
timing of sensitization against DSAs can be divided into the pre- and posttransplant 
periods [4]. The standard method to detect preformed antibodies at the time of HTx 
has been the complement-dependent cytotoxicity (CDC) test using recipient serum 
and donor leukocytes [5]. In Japan, only the donor heart with negative prospective 
CDC crossmatching with T lymphocytes has been transplanted, and none of 512 
HTx consecutive recipients transplanted between 1999 and 2019 in Japan experi-
enced hyperacute rejection (HAR) [6]. Although flow cytometry has been recently 
recommended to crossmatch to select the recipient in the world in solid organ 
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transplantation, flow cytometry is too sensitive to select the recipient, because not 
all DSAs determined by flow cytometry are always cytotoxic to the cardiac graft 
cells [7–9]. Posttransplant antibodies produced before and after HTx are currently 
screened for evaluating AMR development using single antigen Luminex bead (SAB) 
assay or panel reactive antibodies (PRA) test to detect DSAs in the recipient serum. 
However, their clinical impact is not clear and may be less elucidated in HTx. Further 
optimal protocol for management strategies for AMR to reflect clinical prognosis is 
needed [4, 9]. A detection of circulating complement binding DSAs may be promis-
ing. We review the role of the novel management method using complement binding 
ability assay in prevention, diagnosis, therapy, and monitoring of AMR in HTx.
2. Overview of AMR in HTx
HAR, the immediate form of AMR may occur within 0 to a few days after HTx 
if a certain level of preformed DSAs exists in the recipient serum. Early AMR may 
occur during the first month, usually within 1 or 2 weeks after HTx because of 
newly production of de novo DSAs or enhanced production of preformed DSAs. 
These early type AMRs are usually associated with allograft dysfunction and hemo-
dynamic compromise [2–4, 9–11]. Late AMR may occur months to years after HTx, 
most likely due to enhanced recognition [10, 12–15]. Approximately 50% of HTx 
recipients who develop rejection later than 7 years after HTx are associated with 
evidence of AMR [16]. Up to 24% of cases with late AMR has been reported concur-
rent with cellular rejection [17]. As more sensitive diagnostic tools have become 
available for detecting AMR in HTx, the evidence that AMR is a wide spectrum 
of immunologic injury that ranges from subclinical, histological, immunologic, 
serological findings and/or graft dysfunction was increased [4, 9, 18].
2.1 Clinical features and diagnosis of AMR in HTx
2.1.1 Hyperacute rejection in HTx
HAR is a rare cause of primary cardiac graft failure occurring within minutes to 
hours of aortic unclamping with a high mortality rate of around 70% in HTx [19, 20]. 
Preformed antibodies directed against donor HLA class I antigens or ABO antigen 
expressed on the donor vascular endothelium mediate complement deposition with 
widespread hemorrhage and thrombosis within the cardiac allograft [20]. HLA class 
II molecules are not usually expressed on the donor vasculature, but they can be 
induced by inflammation and injury associated with procurement and preservation 
of the heart graft. At last, antibodies against non-HLA endothelial antigens may also 
lead to HAR. Previous blood product transfusions (particularly platelets), mechani-
cal circulatory support (MCS), pregnancy, and previous transplantation may 
increase the likelihood of the presence of preformed DSAs. The use of leukocyte-
depleted transfusions may decrease the risk for DSA production. To prevent HAR, 
CDC PRA screening is used to determine the presence of circulating DSAs [5]. In 
Japan, by routinely performing prospective CDC crossmatching with T lymphocytes 
since the first HTx in 1999, no HTx recipients experienced HAR [6]. A higher PRA 
is associated with worse AMR rates and poorer overall survival [21]. In patients 
with a high percentage of PRAs (>10%), perioperative plasmapheresis combined 
with immunoglobulin therapy may be used to reduce the incidence and severity of 
HAR. These interventions have allowed for transplantation between donors and 
recipients with positive crossmatches. HAR is manifested as severe biventricular 
failure that, if immediate re-HTx cannot be carried out, is usually fatal [4, 9, 20].
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2.1.2 Acute antibody-mediated rejection in HTx
Symptoms of acute AMR are those of right and left ventricular systolic and 
diastolic dysfunction and include exertion dyspnea, orthopnea, paroxysmal 
nocturnal dyspnea, high jugular venous pressure, edema, and abdominal disten-
tion. In infants, those can include feeding intolerance, irritability, and poor body 
weight gain. Acute AMR is associated with hemodynamic compromise in 10–47% 
of cases [2, 4, 9, 18]. The symptoms and signs of hemodynamic compromise have 
been highly variable, and the spectrum of cardiac graft dysfunction may range from 
decreased ejection fraction to cardiogenic shock requiring inotropic support and/or 
MCS [18].
2.2 Pathological diagnosis of AMR
Although multiple imaging tools have been developed in the detection of AMR 
as well as cellular rejection, the best diagnostic strategies for AMR have not been 
established. Therefore, endomyocardial biopsy (EMB) remains the “gold standard” 
for establishing the diagnosis of AMR. Recent novel diagnosis criteria for AMR 
consist of immunopathologic criteria (Table 1) in addition to the clinical manifesta-
tion of AMR [3, 19].
3. Management of AMR
3.1 Preventive method related to AMR
3.1.1 Desensitization strategies
Specific preventive strategies are needed to enable successful HTx in highly 
sensitized patients, because the presence of DSAs reduces the chance to obtain 
compatible donors, extends waiting times to HTx, increases the risk of mortality 
during awaiting HTx, and raises the risks of acute AMR and cardiac allograft vas-
culopathy after HTx [22]. Despite the emergent application of the promising agents 
such as bortezomib which is a 26S proteasome inhibitor and eculizumab which is 
Grade Definition Substrates
pAMR 0 Negative for pathological 
AMR
Histological and immunopathologic studies are both 
negative
pAMR 1 (H+) Histologic AMR alone Histological findings present, and immunopathologic 
findings are negative
pAMR (I+) Immunopathologic AMR 
alone
Histologic findings are negative, and immunopathologic 
findings are positive (CD68+ and/or C4d+)
pAMR2 Pathologic AMR Histologic and immunopathologic findings are both present
pAMR3 Severe pathologic AMR Interstitial hemorrhage, capillary fragmentation, mixed 
inflammatory infiltrates, endothelial cell pyknosis, and/or 
karyorrhexis and marked edema and immunopathologic 
findings are present. These cases may be associated with 
profound hemodynamic dysfunction and poor clinical 
outcomes
AMR, antibody-mediated rejection; pAMR, pathological AMR.
Table 1. 
Recent novel diagnosis criteria in immunopathologic features.
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a recombinant anti-C5 monoclonal antibody, a significant knowledge discrepancy 
remains with the current data for desensitization, investigated mostly from non-
heart organ living donor transplants [23–28] and small observational studies in 
HTx [29–32]. The ideal desensitization strategy remains elusive especially in the 
HTx field. Moreover, clinical modalities to evaluate the efficacy of desensitization 
therapy are limited. Importantly, long-term outcomes and cost-effectiveness of 
desensitization strategies in HTx have not been well evaluated [4, 9].
3.1.2 Recipient selection in patients with preformed DSAs
As CDC assay is most clinically relevant methods for preventing accelerated 
early AMR as well as HAR in HTx [4, 9] but needs the technical expertise and 
experience, in many countries, before transplantation, the potential recipient is 
screened for circulating anti-HLA antibodies by using SAB assay or PRA test. If 
the percentage of PRA test is greater than 5–15%, most cardiac transplant centers 
require a negative prospective crossmatch between donor and recipient sera. 
However, the requirement for prospective crossmatch, which delays organ harvest-
ing, may remarkably prolong a recipient’s waiting time. On the other hand, in Japan, 
prospective CDC crossmatching with T lymphocytes has been routinely performed 
and completely avoided HAR since HTx program was started in 1999 [6]. But HTx 
must avoid false negatives because graft failure due to HAR may be directly life-
threatening, so might need more sensitive tests.
3.2 Therapeutic method of AMR
3.2.1 Treatment of hyperacute rejection
According to the ISTH guideline 2016 [18], treatment for HAR should be 
initiated as soon as the diagnosis is defined, even when the patient is still in the 
operating room. Treatments for HAR include (1) high-dose intravenous (IV) 
corticosteroid (CS); (2) plasmapheresis; (3) IV immunoglobulin (IVIg); (4) cyto-
lytic immunosuppressive therapy, such as antithymocyte or lymphocyte globulin; 
(5) calcineurin inhibitor (CNI) [cyclosporine (CYA) and tacrolimus (Tac)] and 
metabolic cycle inhibitors (i.e., mycophenolate mofetil; MMF); (6) IV inotropes 
and vasopressors; and (7) MCS.
Intraoperative myocardial biopsy is strongly recommended to confirm the 
diagnosis of HAR. Urgent re-HTx may be considered if the above therapies do not 
restore adequate cardiac graft function, but re-HTx for HAR has a considerably high 
mortality rate.
3.2.2 Treatment of acute antibody rejection (AMR)
Guidelines for treatment have recently been recommended by the ISHLT 2016 [18].
Class II a recommendations are followed.
1. To restore the immune-mediated cardiac graft injury in AMR: (1) high-dose IV 
CS and (2) cytolytic immunosuppressive therapy
2. To reduce circulating DSAs or their reactivity: (1) plasmapheresis, (2) immune 
apheresis (immunoadsorption), and (3) IVIg
3. To keep adequate hemodynamics: (1) IV inotropes and vasopressors and 
(2) MCS
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4. When AMR is suspected, immunohistochemistry stains for complement split 
products (i.e., C4d) and possibly antibody should be added to standard histo-
logic examination for EMB
5. The presence, quantity, and specificity of DSAs in the recipient serum should 
be screened
6. Follow-up EMB including immunohistochemistry staining should be per-
formed 1–4 weeks after initiation of therapy
7. Maintenance immunosuppressive therapy after AMR treatment may be ad-
justed: (1) increase in the dose of current immunosuppressive agent(s), (2) 
addition of new agent(s), and (3) conversion to different agent(s) as shown 
below
Class II b recommendations are followed.
1. Systemic anticoagulation may reduce intravascular thrombosis in the cardiac 
allograft
2. Emergent re-HTx may be considered if the above therapies do not restore ad-
equate cardiac graft function, but prognosis in this situation is poor
The benefit of treating subclinical AMR has not been elucidated. AMR might 
be a clinical-pathological continuation which starts with a latent immunological 
response of circulating DSAs with C4d deposition without clinical or histologi-
cal changes, to a subclinical AMR, and finally to symptomatic AMR. A recent 
consensus recommends treating AMR in the presence of graft dysfunction regard-
less of histopathological finding, pAMR 2 in the absence of graft dysfunction if 
DSAs possibly relevant to AMR are present, and pAMR 3 regardless of the clinical 
findings [18].
3.2.3 Maintenance immunosuppressive strategies after treating AMR
The principles for the post-AMR management consist of reducing circulating DSAs 
and suppressing production of additional DSAs and T- and B-lymphocyte responses. 
However, currently there are only recommendations based on consensus [18].
The current available therapies are as follows: (1) suppression of the 
T-lymphocyte response (i.e., CS, MMF, cytolytic immunosuppressive therapy, 
photopheresis, or total lymphoid irradiation), (2) depletion of circulating DSAs 
(i.e., plasmapheresis), (3) suppression of residual DSAs (i.e., IVIg), (4) depletion of 
B lymphocytes (i.e., CS, rituximab, or splenectomy), (5) depletion of plasma cells 
(i.e., bortezomib), and (6) suppression of complement (i.e., eculizumab, IVIg).
4.  What are the methods of detecting DSAs most relevant to clinical 
outcomes?
AMR in HTx is caused by the complex pathogenesis and immunopathologic 
pathway [2–4, 9, 18]. AMR develops when recipient serum contains DSAs against 
the endothelial layer of the cardiac allograft. Antibodies bind complement 
and activate the complement cascade, resulting in endothelial and myocardial 
injury. Complements, its fragments, and immunoglobulin are deposited on the 
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endothelium of the cardiac graft microvasculature and proceed inflammatory 
responses, such as release of cytokines, infiltration of macrophages, increased 
vascular permeability, and microvascular thrombosis, which results in cardiac graft 
dysfunction [2, 3].
The presence of circulating DSAs in HTx negatively impacts clinical outcome 
after HTx. Due to different clinical implications, DSA can be divided into pre-
formed and de novo DSA by the time detected. Preformed antibodies can reduce 
the possibility to obtain a compatible donor heart and may increase the risk of 
AMR after HTx. With regard to post-HTx setting, considerable evidences about the 
impacts of DSAs on outcomes such as rejection, cardiac allograft vasculopathy, and 
survival have been reported [2–4, 9].
4.1 Currently used methods to assess anti-HLA antibodies
There are several anti-HLA antibody screening methods, each with varying 
sensitivities, specificities, and clinical usefulness [5–7].
4.1.1 Crossmatching
4.1.1.1 Complement-dependent cytotoxicity (CDC) test
Patel and Terasaki reported a significant correlation between a positive 
CDC crossmatch (or lymphocyte cytotoxicity test methods) and hyperacute 
and accelerated acute kidney graft dysfunction in 1969 [5]. Recipient serum 
is mixed with T and B lymphocytes from the donor and complement source is 
added. A cytotoxic reaction suggests the presence of complement fixing DSAs. 
The advantage of the test is its high positive predictive value for HAR or early 
acute AMR, making it well-defined that a patient should not undergo transplant 
with a particular donor. The disadvantage of this test is that it requires donor 
leukocytes and recipient serum prior to transplantation and that it is based on 
in vitro complement-mediated lysis which may not be of physiological relevance. 
This method using T lymphocytes has been used for prospective crossmatching 
in Japan to select the recipient in heart, lung, pancreas, and kidney transplanta-
tion. And that using B-lymphocytes is used for reference crossmatching to select 
the recipient transplanted with these organs according to each transplant center 
protocol [6, 9].
4.1.1.2 Flow cytometry crossmatching
Flow cytometry crossmatching method consists of reacting recipient serum with 
donor lymphocytes and adding a fluorescent-labeled anti-human immunoglobulin 
secondary antibody [7, 8]. The shifts in the distribution of fluorescence signals 
are detected in this assay. In flow cytometric crossmatching, complement sources 
are not added. As this assay is more sensitive at detecting physiological reactions 
than CDC, this assay is widely used for crossmatching in many countries in solid 
organ transplant. However, not all DSAs determined by this method are cytotoxic 
to the cardiac graft because this assay cannot evaluate complement fixation ability 
of DSAs [7, 8]. The false positivity of this method may decrease the likelihood of 
obtaining a compatible donor heart. Therefore, due to extremely more severe organ 
shortage in Japan than other developed countries, flow cytometric crossmatching is 
used only as a reference to select the heart recipient to increase a chance to obtain a 
compatible donor heart [9].
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4.1.1.3 Virtual crossmatching
The virtual crossmatch protocol was introduced on October 2006 at Texas 
Transplant Institute for all sensitized patients waiting for deceased donor kidney 
transplantation [33]. Briefly, HLA typing antibody screening is performed using 
flow PRA screen beads (One Lambda) for the presence or absence of HLA class I 
and II antibodies. HLA class I and II single antigens (SA) include A, B, and Cw loci 
and DR, DQ , DRw, and DP loci, respectively. All final crossmatches are carried out 
by flow cytometry.
The rationale for recommending virtual crossmatching is double staged: (1) 
use methods having the sensitivity of DSA detecting assay nearly equal to the 
CDC crossmatch test and (2) reduce the time and cost for choosing a compatible 
deceased donor by no longer performing prospective CDC crossmatch test. By 
undoing prospective CDC crossmatch test, the average turnaround time is reduced 
by 3 hours which allows quicker organ allocation with reasonable assurance that the 
sensitized patients at the top waiting list will have an adequate deceased donor with 
negative final crossmatch [33].
4.1.2 Screening for the presence or absence of DSAs
4.1.2.1 CDC panel reactive antibody screening
The method to detect the anti-HLA antibodies had historically been the CDC 
assay [5]. The sera were analyzed using a manufactured frozen lymphocyte panels, 
which consist of mononucleated cells isolated from 60 or 72 healthy individuals of 
known HLA typing of A and B locus antigens [34]. However, as these CDC PRA cell 
panel are currently less available, and its technique is more complicated than flow 
PRA screening, more sensitive assays shown below are widely used. However, CDC 
PRA remains an alternative to define the level of patient desensitization, in cross-
matching with a specific donor to avoid HAR [4, 9].
4.1.2.2 Flow PRA screening
Flow PRA screening uses panels of beads coated with the equivalent of whole 
cell’s HLA class 1 or 2 [35]. Often used for initial screening, it gives a qualitative 
result on an incomplete panel. Luminex PRA uses panels of beads also coated with 
the equivalent of whole cell’s HLA class 1 or 2. PRAs are more sensitive than CDC 
but less sensitive than SAB assay. These PRA methods require expert interpretation 
and there is a possibility to miss antibodies [9].
4.1.2.3 Single antigen Luminex bead assay
SAB assay uses microbeads coated with unique HLA antigen/allele on each 
bead [35] and detects a specific anti-HLA IgG antibody using a single HLA 
antigen/allele being interested. SAB assays are the most sensitive, specific, and 
definitive of the bead assays, but are often considered overreactive, with ambigu-
ous clinical significance. SAB assays are now commonly applied for determining 
specificities and quantities of antibodies against antigen of interest. SAB assay 
for preformed HLA antibodies is useful as a reference to establish the protocol 
of desensitization strategies before and at the time of HTx, to select an adequate 
compatible donor heart, and to decide posttransplant immunosuppressive 
 regimen [4, 9, 18].
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4.2 Complement binding antibodies
Since complement activation plays a major role in antibody-mediated immune 
response on transplanted graft, detection of ability of antibodies to bind specific 
complement components seems to provide further clinical benefit for the diagnosis 
of AMR. Conventional solid-phase assays, such as SAB assay, cannot distinguish 
between complement binding and non-complement binding antibodies, and 
the intensity of antibodies by mean fluorescence intensity (MFI) may not be the 
best index of cytotoxic ability of antibodies because not all antibodies with high 
MFI may be prejudicial to graft function [9, 36]. Detection of antibodies capable 
of binding the component of classical pathway, such as C1q, C4d, or C3d, may 
indicate the potential for antibody-mediated cell injury. The complement binding 
antibody assay may be potentially more specific than conventional solid-phase 
assays to predict immune response to donor antigen and more sensitive than CDC 
assay. Although the diagnostic approach using complement binding DSAs seems 
to be supportive for the more adequate donor matching with sensitized recipients 
than the CDC assay or other conventional indirect methods such as SAB assay, the 
usefulness of complement-fixing DSA assay for desensitization or posttransplant 
monitoring in HTx remains unclear.
4.2.1 Cascade of complement activation
Complemental cascade is a multifunctional system of receptors and regulators 
as well as effector molecules [37]. The classical complement pathway can be initi-
ated by the binding of antigen–antibody complexes to the C1q protein. The binding 
of C1q changes conformation and activates serine protease C1r which then cleaves 
and activates the serine protease C1s. The activated C1s cleaves C4, yielding C4a 
and C4b, and C2, yielding C2a and C2b. The larger fragments C4b and C2a generate 
the classical pathway C3 convertase. This convertase then cleaves C3 into a small 
C3a fragment and a larger C3b fragment. While the anaphylatoxin C3a interacts 
with its C3a receptor to recruit leukocytes, C3b contributes to further downstream 
complement activation. A larger C3b binds to the cell surface. C4b can be regulated 
by decay accelerating factor dissociating C4b and C2a. Successful regulation of C4 
by factor 1 leaves C4d as an end product that truncates the complement cascade. 
C3b is more versatile than C4b. Factor I also can cleave C3b to ultimately produce 
C3d, which is a ligand for complement receptor type 2 on B lymphocytes. Moreover, 
C3b can generate an alternative C3 convertase with factor B, which allows C3b to 
start an amplification loop that can greatly increase the amount of C3b deposited 
on a cell surface. Finally, C3b binds to the C3 convertase, to generate C5 convertase, 
which cleaves C5 into C5a and C5b. Subsequent interactions between C5b and other 
terminal components C6, C7, C8, and C9 generate the membrane attack complex 
(MAC) or the C5b-9 complex which makes pores on the target cell membranes to 
lysing (Figure 1).
4.2.2 Principles of C1q, C3d, and C4d binding assays
The C1q binding SAB (C1q SAB) assay (One Lambda, Canoga, USA) aims 
at defining HLA antibodies capable to bind C1q. Serum samples are first heat-
inactivated to eliminate interference of endogenous complement components. Sera 
are incubated together with recombinant C1q. An antibody capable to bind C1q is 
detected by a phycoerythrin (PE)-conjugated anti-C1q antibody (Figure 2) [38]. As 
IgM or IgG cannot be identified by this anti-C1q antibody, C1q binding anti-HLA 
antibodies detected can be either IgM or IgG isotype.
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Whereas C1q binding to antigen-bound antibody is the first step in activating 
classical complement pathway, binding of C1q to antibodies does not necessarily 
mean that all downstream events in this cascade will occur, as has been shown for 
human monoclonal HLA antibodies [39]. In this regard, C3d and C4d binding 
assays might be a more accurate modality to predict in vivo complement activation 
causing cell injury. As C1q binding to antibody triggers complement cascade once 
and then complement split products, such as C3d are clustered on beads in turn, the 
C3d assay may have a higher sensitivity than the C1q assay [40, 41]. As schematized 
in Figure 2, the C3d assay is like the C1q assay in methodology but does not need 
a recombinant complement product. Following an initial incubation of serum 
Figure 1. 
Complement of classical complement pathway.
Figure 2. 
Principles of C1q and C3d binding assays. (A) C1q binding assay: Heat-inactivated patient serum is incubated 
with single antigen beads (SABs) and recombinant C1q. Following a wash step, phycoerythrin-conjugated 
anti-C1q antibody is added to detect C1q binding HLA antibodies. (B) C3d binding assay: Patient serum is 
first incubated with SABs. Following binding of HLA antibodies to the beads, a healthy control serum as the 
complement source is added for further incubation. Following a wash step, PE conjugated anti-C3d antibody is 
added to detect C3d deposition on the beads.
Immunosupression
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samples with SABs, healthy control human serum is added as a source of comple-
ment, and then an anti-human C3d detection antibody is added.
4.3 Significance of anti-HLA antibodies before and after HTx
4.3.1 Preformed anti-HLA antibody (anti-HLA antibody made before HTx)
Clinical significance of pretransplant sensitization and current modality to 
detect preformed DSAs are already described above. In summary, as non-CDC 
crossmatching are more sensitive for detecting DSAs than CDC assay, flow 
cytometry crossmatching or virtual crossmatching is more prevalent in the world. 
However, in patients negative for CDC crossmatching, positive for flow cytometry 
crossmatching is not associated with higher incidence or severity of cardiac graft 
failure than negative for flow cytometry crossmatching. Its high sensitivity for 
DSA detection may result in increasing of false positive for predicting HAR or 
early acute AMR and decreasing the opportunity of sensitized candidates to obtain 
a compatible donor heart especially in Japan where donor shortage is extremely 
severe [6]. Therefore, more precise sensitive tests should be added to CDC-based 
strategies to avoid the false positive. In recent years, there has been a great interest 
in the detection of DSAs with complement binding capacity to overcome these 
issues.
4.3.2 Donor-specific anti-HLA antibodies posttransplant
The development of anti-DSAs after HTx has been implicated in allograft injury. 
DSAs which are produced by sensitization after transplantation are called de novo 
DSA. Both preformed and de novo DSAs should be assessed for monitoring the 
efficacy of desensitization therapy and posttransplant immunosuppressive regi-
men. Solid-phase assays, such as the SAB assay, are recommended to detect circulat-
ing antibodies. A percent of PRA greater than 10% or preformed DSAs at the time 
of HTx increases the risk for suboptimal post-HTx outcome. Monitoring for DSAs 
should be performed at 1, 3, 6, and 12 months post-HTx in accordance with ISHLT 
guidelines [18]. Patients at low risk should be monitored annually, and sensitized 
patients should be monitored more frequently. In any patient with symptoms or 
signs of graft dysfunction, DSA testing should be performed. The presence of DSA 
with graft dysfunction including restrictive physiology should be considered for 
AMR treatment.
4.4 Clinical significance of complement binding antibody in AMR
Although DSAs can induce a wide spectrum of graft injuries from no damage 
to severe myocardial or endothelial injury, not all DSAs are responsible for causing 
AMR or the poor prognosis post-HTx [41–43]. Since improved analysis is needed 
to better distinguish DSAs relevant to clinical outcome, SAB assays for detecting 
complement binding capability of HLA antibodies (C1q, C3d) have been introduced 
[43–46] with the hypothesis that complement binding antibodies induce more 
severe graft injury than their non-activating counterparts [41]. Several studies have 
revealed significant association of C1q or C3d binding DSAs with high incidence 
of AMR or poor graft or patient survival [44, 45]. Although several studies have 
compared two complement binding assays, the superiority or difference of these 
diagnostic utilities remains unclear. Therefore, C1q or C3d binding DSA assay can-
not be a definitive method to detect DSAs relevant to AMR. However, these assays 
can be a supportive method to decide immunotherapy.
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4.4.1 Clinical applications of C1q biding assay for preformed DSA
Over the past two decades, sensitization rates in adult HTX candidates (PRA > 
10%) have doubled from 7.7 to 13.5% [1]. An increased incidence is expected due 
to the increased application of left ventricular assist devices (LVADs) as a bridge to 
HTx strategy, improved congenital heart disease surgery with patients surviving 
to require HTx, and increased re-HTx. Although development of desensitization 
strategies is needed to enable successful HTx in these highly sensitized patients, 
LVAD infections remain the most frequent complication of LVAD care with high 
morbidity and mortality, and desensitization method should not be over-immuno-
suppressive. Therefore, clinical tools to evaluate DSAs relevant to desensitization 
efficacy are more required in HTx than in other solid organ transplantations.
In our institute, we have used C1q SAB assay as an auxiliary method to evaluate 
the effects of desensitization therapy.
4.4.1.1 Case
A 43-year-old gentleman with dilated cardiomyopathy who had been supported 
by a NIPRO extracorporeal LVAD (NIPRO Corp, Osaka, Japan) for 1677 days 
underwent HTx. As he had received a transfusion of packed red blood cells and 
platelets at the time of LVAD implantation and packed red blood cells for gastroin-
testinal bleedings several times, he had high intensity anti-HLA antibodies and had 
not been selected as a recipient of several donor hearts due to positive CRC cross-
matching against the particular donor T lymphocytes. Therefore IVIg (5 g/day) was 
given for 5 days for desensitization treatment. The antibody level of eight anti-HLA 
antibodies was higher than 15,000 MFI assessed by SAB assay before IVIG treat-
ment. However, in seven of those antibodies, the antibody level assessed by C1q 
SAB assay was lower than that assessed by SAB assay. Although the antibody levels 
of anti-HLA antibodies assessed by SAB assay 1 month after IVIG treatment were 
higher than those before IVIG treatment, the antibody levels of all the anti-HLA 
antibodies assessed by C1q SAB assay 1 month after IVIG treatment were lower than 
those before IVIG treatment (Figure 3).
Figure 3. 
Changes in mean fluorescence intensity by single antigen Luminex bead assay and C1q binding SAB assay 
before and 1 month after desensitization treatment. SAB, single antigen Luminex bead assay; C1q SAB, C1q 
binding SAB assay; IVIg, intravenous immune globulin.
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After three courses of IVIg desensitization, he underwent HTx with a donor 
heart with negative prospective CDC crossmatching using the donor T lympho-
cytes. Although virtual SAB crossmatch showed preformed DSAs against HLA loci 
A2, A26, B35, and B65 with high MFI (Table 1), C1q SAB revealed that C1q binding 
abilities of these antibodies were all negative. Then we decided not to perform plas-
mapheresis or antithymocyte globulin in order to avoid over-immunosuppression. 
20 mg of basiliximab was given IV just after discontinuing cardiopulmonary bypass 
and confirming hemostasis and at the 4th postoperative day. Maintenance immu-
nosuppressive regimen consisted of Tac, MMF, and CS. Although routine EMB 
revealed pAMR 1 at 1 week after HTx, he experienced no hemodynamic compro-
mise or cardiac graft dysfunction, and EMB revealed no further AMR or acute 
cellular rejection. He is currently at home with good cardiac graft function 2.5 years 
after HTx (Table 2).
4.4.2  Clinical application of C1q binding assay for maintenance immunosuppressive 
strategies
It is also known that not all patients with persistent production of DSA suffer 
loss of their allografts, indicating that DSAs are not equal in terms of their detri-
mental effects on allograft function. A C1q-positive de novo DSA has been reported 
to be associated with an increased rate of AMR and transplant glomerulopathy in 
kidney transplantation [46–49]. However, the prevalence and clinical significance 
of DSA characterized by C1q binding have not been well investigated in adult HTx 
patients [50–52].
In our clinical experience of 64 consecutive patients who received a HTx 
between May 1999 and January 2015, 12 patients had DSAs after HTx, but none had 
C1q binding antibodies. There were no significant differences in overall or cardiac 
event-free patient survival between DSA positive and negative patients with the 
same immunosuppressive regimen post-HTx (Figure 4). These data suggested that 
no reinforcement immunosuppressive regimen is needed, if the patient had no C1q 
binding DSA midterm after HTx [53].
A B Cw
HLA class I Recipient 33 — 44 — 14 —
Donor 2 26 35 62 1 9
DSA 
(MFI)
Pre-IVIG SAB assay 11,429 57.3 13,725 13,911 90.4 397
C1q SAB 
assay
0 0 0 0 1.35 0
At HTx SAB assay 3911 10.7 4629 7631 72.7 77.4
C1q SAB 
assay
3.7 0 0 6.4 1.2 0.9
2 months 
after HTx
SAB assay 315 37.9 633 3025 1300 12.1
C1q SAB 
assay
0 0 0 0 0 0
HLA, human leukocyte antigen; DSA, donor-specific anti-HLA antibody; MFI, mean fluorescent intensity; SAB, 
single antigen Luminex bead assay; C1q SAB, C1q binding SAB assay; IVIg, intravenous immune globulin.
Table 2. 
Human leukocyte antigen class I of the recipient and the donor and the antibody level of the donor-specific 
HLA antibodies assessed by single antigen Luminex bead assay and C1q binding SAB assay before IVIG 
therapy, at the time of heart transplantation and 2 months after heart transplantation.
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5. Conclusion
Over the past decades, sensitization rates in adult HTX candidates have doubled 
patients due to the expanding application of LVAD and prolonged waiting period. 
Sensitized HTx candidates have extended the waiting times for obtaining a compat-
ible donor heart and increased mortality while waiting. An effective desensitization 
strategy has the potential to increase access to and success of HTx in sensitized 
patients, thus improving outcomes for this disadvantaged and growing transplant 
population. Although CDC PRA screening remains a standard method to define 
the efficacy of desensitization therapy, CDC PRA cell panels are currently less 
available, and its technique is complicated. Therefore, more sensitive assays flow 
PRA screening or SAB are widely used. However, flow cytometry is too sensitive to 
select the recipient, because not all DSAs determined by this method are cytotoxic 
to the cardiac graft. Although C1q or C3d binding DSA assay cannot be a definitive 
method to detect DSAs relevant to AMR, these assays can be a novel supportive 
method to decide immunotherapy.
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Figure 4. 
Cumulative overall (A) and cardiac event-free (B) survival in patients with and without developing 
DSA. DSA, donor-specific anti-human leukocyte antigen; HTx, heart transplantation.
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